Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Acer Therapeutics Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. Its lead product candidate, ACER-001, targets urea cycle disorders and is currently in late-stage clinical development, providing a unique position in a niche market with limited competition.
Acer Therapeutics aims to generate revenue primarily through the commercialization of its lead product, ACER-001, which is designed to treat urea cycle disorders. The company has a strong focus on rare diseases, allowing it to potentially command premium pricing due to the lack of alternative treatments. Additionally, it may pursue partnerships or licensing agreements to expand its market reach.
Clinical trial results for ACER-001, particularly Phase 3 outcomes
Regulatory approvals from the FDA or EMA
Partnership announcements or licensing deals
Market entry strategies for ACER-001 in key geographies
Regulatory changes that could impact drug approval processes
Technological advancements in competing therapies
Emergence of new therapies for urea cycle disorders
Potential for larger pharmaceutical companies to enter the rare disease market
High cash burn rate with no current revenue generation
Dependence on future funding rounds to sustain operations
low - The demand for rare disease treatments is less correlated with economic cycles, as these conditions require ongoing treatment regardless of economic conditions.
High interest rates could increase the cost of capital for Acer, impacting its ability to fund R&D and clinical trials, which are critical for its growth.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has shown significant volatility, with a 1-year return of -79.8%.
